NASDAQ · ACET
Healthcare · Biotechnology
$9.52
Down-$0.01 (-0.10%)
Updated Sep 13, 2026, 7:28 PM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
ACET closed at $9.52 after 19 trading sessions, up 8.92% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $9.65 | $9.80 | $9.38 | $9.52 | 119.5K |
| Sep 10, 2026 | $9.46 | $9.68 | $9.31 | $9.53 | 119K |
| Sep 9, 2026 | $9.67 | $9.95 | $9.435 | $9.54 | 93.33K |
| Sep 8, 2026 | $9.61 | $9.97 | $9.38 | $9.73 | 81.85K |
| Sep 4, 2026 | $9.33 | $9.76 | $9.261 | $9.59 | 44.61K |
| Sep 3, 2026 | $9.26 | $9.64 | $9.0481 | $9.43 | 78.76K |
| Sep 2, 2026 | $9.35 | $9.65 | $9.0009 | $9.26 | 60.95K |
| Sep 1, 2026 | $8.87 | $9.45 | $8.77 | $9.26 | 134.13K |
| Aug 31, 2026 | $8.92 | $9.07 | $8.62 | $8.70 | 112K |
| Aug 28, 2026 | $9.22 | $9.245 | $8.76 | $9.06 | 111.65K |
| Aug 27, 2026 | $9.00 | $9.18 | $8.8408 | $9.01 | 261.59K |
| Aug 26, 2026 | $8.98 | $9.04 | $8.63 | $8.95 | 119.34K |
| Aug 25, 2026 | $8.98 | $9.145 | $8.78 | $9.00 | 69.88K |
| Aug 24, 2026 | $9.21 | $9.21 | $8.74 | $8.90 | 64.33K |
| Aug 21, 2026 | $9.42 | $9.63 | $9.10 | $9.19 | 80.5K |
| Aug 20, 2026 | $9.6155 | $9.6466 | $9.08 | $9.38 | 65.53K |
| Aug 19, 2026 | $8.99 | $9.60 | $8.99 | $9.49 | 84.85K |
| Aug 18, 2026 | $8.75 | $9.22 | $8.70 | $9.11 | 101.41K |
| Aug 17, 2026 | $8.46 | $8.99 | $8.46 | $8.74 | 93.23K |
The latest Smart Investors Daily articles mentioning ACET.
ACET research
Company profile and research snapshot.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Guggenheim | Buy | — |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 13, 2026 | Guggenheim | Buy | — |
| Jan 21, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 6, 2026 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 3, 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Yahoo · Sep 3, 2026
Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far this year.
Yahoo · Sep 2, 2026
REDWOOD CITY, Calif., September 02, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference being held from September 14-16, 2026, in New York.
Yahoo · Sep 1, 2026
REDWOOD CITY, Calif., September 01, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of prulacabtagene leucel (prula-cel) in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (L
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ACET.
No results
No recent SID articles mention ACET.
